{Reference Type}: Journal Article
{Title}: Chronic Lung Allograft Dysfunction.
{Author}: Venado A;Kukreja J;Greenland JR;Venado A;Kukreja J;Greenland JR;
{Journal}: Thorac Surg Clin
{Volume}: 32
{Issue}: 2
{Year}: May 2022
暂无{DOI}: 10.1016/j.thorsurg.2021.11.004
{Abstract}: Chronic lung allograft dysfunction (CLAD) is a syndrome of progressive lung function decline, subcategorized into obstructive, restrictive, and mixed phenotypes. The trajectory of CLAD is variable depending on the phenotype, with restrictive and mixed phenotypes having more rapid progression and lower survival. The mechanisms driving CLAD development remain unclear, though allograft injury during primary graft dysfunction, acute cellular rejection, antibody-mediated rejection, and infections trigger immune responses with long-lasting effects that can lead to CLAD months or years later. Currently, retransplantation is the only effective treatment.